Donor TM6SF2 rs58542926 Genotype is a Risk Factor for Liver Graft Steatosis
1Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
2Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
3Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
4Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
5Medical Statistics Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Meeting: 2018 American Transplant Congress
Abstract number: A232
Keywords: Biopsy, Gene polymorphism, Liver transplantation, Metabolic complications
Session Information
Session Name: Poster Session A: Liver Retransplantation and Other Complications
Session Type: Poster Session
Date: Saturday, June 2, 2018
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Background & Aims: The rs58542926 c.449C>T (p.E167K) polymorphism in TM6SF2 (transmembrane 6 superfamily member 2) is one of genetic factors predisposing to nonalcoholic fatty liver disease. We aimed to evaluate the effect of recipient and donor TM6SF2 rs58542926 genotypes on liver graft fat content after liver transplantation.
Methods: Steatosis was evaluated in liver graft biopsies from 268 adult recipients transplanted between 1995 and 2010. During a period of 2 years after transplantation, 18 patients developed grade 3 steatosis; 15 patients, grade 2 steatosis; 96 patients, grade 1 steatosis, and 139 patients, grade 0 steatosis. The influence of recipient and donor TM6SF2 rs58542926 and PNPLA3 (patatin-like phospholipase 3) rs738409 genotypes and clinical data on steatosis grade were analyzed using ordinal logistic regression method.
Results: The TM6SF2 rs58542926 CC/CT/TT genotype frequencies were 0.772/0.205/0.022 in graft recipients and 0.843/0.153/0.004 in liver graft donors, respectively. Presence of the TM6SF2 c.449T allele in donor (OR 2.60; 95%CI 1.30–5.10), PNPLA3 c.444G allele in donor (OR 2.20; 95%CI 1.40–3.30), post-transplant BMI (OR 1.10; 95%CI 1.08–1.20) and serum HDL cholesterol (OR 0.42; 95%CI 0.19–0.94) were independent predictors of increased liver graft fat content on multivariate analysis. The effect of donor TM6SF2 c.449T allele and donor PNPLA3 c.444G allele was additive, with OR 4.90 (95%CI 2.01-13.00) when both variant alleles were present in comparison to OR 2.22 (95%CI 1.42-3.61) when only one of these alleles was present.
Conclusion: Donor TM6SF2 c.449T allele is an independent risk factor for liver graft steatosis after liver transplantation.
CITATION INFORMATION: Mikova I., Neroldova M., Hubacek J., Dlouha D., Kolesar L., Jirsa M., Honsova E., Sticova E., Lanska V., Spicak J., Trunecka P. Donor TM6SF2 rs58542926 Genotype is a Risk Factor for Liver Graft Steatosis Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Mikova I, Neroldova M, Hubacek J, Dlouha D, Kolesar L, Jirsa M, Honsova E, Sticova E, Lanska V, Spicak J, Trunecka P. Donor TM6SF2 rs58542926 Genotype is a Risk Factor for Liver Graft Steatosis [abstract]. https://atcmeetingabstracts.com/abstract/donor-tm6sf2-rs58542926-genotype-is-a-risk-factor-for-liver-graft-steatosis/. Accessed May 16, 2025.« Back to 2018 American Transplant Congress